The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
FDA Drug Approval Summary: Panitumumab (Vectibix™)
Abstract
Learning Objectives: After completing this course, the reader will be able to: Add panitumumab (Vectibix™) to the armamentarium of drugs for colorectal cancer.Identify the patient group that is eligible for panitumumab therapy.Identify biologic agents that have activity in colorectal cancer.List the FDA criteria for the analysis of progression-free survival and for accelerated approval. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cited by
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
The emerging role of photoacoustic imaging in clinical oncology
Lin, L., & Wang, L. V. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00615-3 · Cited by 469
Prognostic and predictive factors in colorectal cancer
Zlobec, I., & Lugli, A. (2008) · Postgraduate Medical Journal · doi:10.1136/jcp.2007.054858 · Cited by 280
Metadata
- Authors
- Giusti, R. M., Shastri, K. A., Cohen, M. H., Keegan, P., & Pazdur, R.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05-01
- Volume
- 12
- Issue
- 5
- Pages
- 577-583
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2065849320
- Cited by
- 214
- References
- 3
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDA Drug Approval Summary: Panitumumab (Vectibix™). https://app.cochat.ai/papers/10.1634/theoncologist.12-5-577
- The paper
- Giusti, R. M., Shastri, K. A., Cohen, M. H., Keegan, P., & Pazdur, R. (2007). FDA Drug Approval Summary: Panitumumab (Vectibix™). The Oncologist. https://doi.org/10.1634/theoncologist.12-5-577
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.